DelveInsight Business Research LLP

DelveInsight launched a new report on Chemotherapy Induced Anemia Epidemiology Forecast to 2030

Some of the key facts of the report

1. The incidence of anaemia in a distinct incidence population was 53.7% overall and 62.7% for patients who received chemotherapy.
2. The development of chemotherapy induced anemia common in patients with hematologic malignant tumors.
3. There has been noted that no gender bias has been observed.
4. The incidence of anemia was higher in patients with advanced stages. Overall, the risk of grade 2+ anemia was increased from 29% in stage I to 49% in stage IV. 

The most common comorbid conditions before starting chemotherapy were hypertension (46.4%), diabetes (22.6%), and renal disease (11.2%). The most common regimen was cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)/rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) (58.7%), followed by bendamustine with or without rituximab (11%).

The incidence of anaemia in cancer patients reported in literature varies significantly, ranging from 20% to 60% at the time of cancer diagnosis and reaching 60–90% during cancer treatments.

Request for sample pages:- https://www.delveinsight.com/sample-request/chemotherapy-induced-anemia-epidemiology-forecast

Scope of the Report

• The Chemotherapy Induced Anemia report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Chemotherapy Induced Anemia Epidemiology Report and Model provide an overview of the risk factors and global trends of Chemotherapy Induced Anemia in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight about the historical and forecasted patient pool of Chemotherapy Induced Anemia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Chemotherapy Induced Anemia
• The report provides the segmentation of the Chemotherapy Induced Anemia epidemiology

Reasons to buy

• The Chemotherapy Induced Anemia Epidemiology report will allow the user to –
• Develop business strategies by understanding the trends shaping and driving the global Chemotherapy Induced Anemia market
• Quantify patient populations in the global Chemotherapy Induced Anemia market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Chemotherapy Induced Anemia therapeutics in each of the markets covered
• Understand the magnitude of Chemotherapy Induced Anemia population by its epidemiology
• The Chemotherapy Induced Anemia Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Table of contents

1. Key Insights 

2. Executive Summary of Chemotherapy Induced Anemia

3. Chemotherapy Induced Anemia: Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Chemotherapy Induced Anemia Epidemiology Scenario in the 7MM (2017- 2030)

5.4. United States Epidemiology

5.4.1. Chemotherapy Induced Anemia Epidemiology Scenario in the United States (2017- 2030)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.1.1. Chemotherapy Induced Anemia Epidemiology Scenario in Germany (2017- 2030)

5.5.2. France Epidemiology

5.5.2.1. Chemotherapy Induced Anemia Epidemiology Scenario in France (2017- 2030)

5.5.3. Italy Epidemiology

5.5.3.1. Chemotherapy Induced Anemia Epidemiology Scenario in Italy (2017- 2030)

5.5.4. Spain Epidemiology

5.5.4.1. Chemotherapy Induced Anemia Epidemiology Scenario in Spain (2017- 2030)

5.5.5. United Kingdom Epidemiology

5.5.5.1. Chemotherapy Induced Anemia Epidemiology Scenario in the United Kingdom (2017-2030)

5.6. Japan Epidemiology

5.6.1. Chemotherapy Induced Anemia Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. Chemotherapy Induced Anemia Treatment and Management

6.2. Chemotherapy Induced Anemia Treatment Algorithm

7. KOL Views

8. Unmet Needs

9.  Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

Request for sample pages:- https://www.delveinsight.com/sample-request/chemotherapy-induced-anemia-epidemiology-forecast

Related reports :-

 Chemotherapy Induced Anemia- Market Insight, Epidemiology and Market Forecast -2030

DelveInsight’ s Chemotherapy Induced Anemia – Market Insights, Epidemiology and Market Forecast – 2030 report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology.

Chemotherapy Induced Anemia – Pipeline Insights, 2020

Chemotherapy Induced Anemia Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Chemotherapy Induced Anemia market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/